LAUSANNE, Switzerland and KOLKATA, India, September 9, 2013 /PRNewswire/ --
Debiopharm Group (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, and TCG Lifesciences Limited (TCGLS) a leading contract research services company in the area of early drug discovery and development, today announced the signature of an exclusive discovery collaboration to develop innovative antibiotics targeting drug-resistant bacteria for community hospital-acquired infections.
Debiopharm is willing to become a key player in the area of antibacterials to fulfill the increasing need of new classes of antibiotics to overcome resistance to current treatment.
Under the terms of the agreement, TCGLS will contribute its expertise in the discovery and optimization of lead compounds whilst Debiopharm will provide drug development expertise and fund the development program.
“We foresee to increase our commitment in this field over next few months through additional partnerships and investments on other innovative targets” said David Deperthes, VP Business Development & Licensing. "We are very enthusiastic about this partnership with TCGLS for the development of novel antibiotics, their extensive experience in medicinal chemistry and infectious diseases is a major asset for the development of Debio 1348. This partnership is key to us to establish a leadership position in the area of antibiotics” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group.
Swapan Bhattacharya, Managing Director of TCG Lifesciences commented: “We are indeed excited about this program which involves a challenging new target that could potentially address the vast incidence of nosoco
|SOURCE The Debiopharm Group|
Copyright©2012 PR Newswire.
All rights reserved